Danaher Co. (NYSE:DHR) Receives $285.55 Average Price Target from Analysts

Danaher Co. (NYSE:DHR) has received a consensus recommendation of “Moderate Buy” from the twenty ratings firms that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $285.55.

Several brokerages recently commented on DHR. Raymond James reduced their target price on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Barclays lowered their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. UBS Group decreased their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus boosted their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Wedge Capital Management L L P NC raised its holdings in shares of Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 38 shares during the period. Meridian Financial Partners LLC increased its holdings in Danaher by 4.4% during the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares in the last quarter. Kovack Advisors Inc. lifted its holdings in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares in the last quarter. Well Done LLC boosted its position in shares of Danaher by 1.2% during the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock worth $987,000 after buying an additional 42 shares during the period. Finally, Waypoint Capital Advisors LLC grew its holdings in shares of Danaher by 0.9% during the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock worth $1,257,000 after buying an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $250.51 on Thursday. The company has a 50 day moving average of $235.33 and a 200-day moving average of $253.62. The company has a market cap of $180.94 billion, a PE ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher has a 1-year low of $225.42 and a 1-year high of $281.70.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.